Therapeutic Moderate Hypothermia and Fever

Author: Marion, D.W.

Source: Current Pharmaceutical Design, Volume 7, Number 15, 1 October 2001 , pp. 1533-1536(4)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Fever above 38C that occurs in patients with acute neurosurgical diseases appears to worsen secondary brain injury and ultimate neurologic outcomes. Laboratory investigations are quite clear regarding the adverse effects of fever in terms not only of functional outcomes, but also histologic and neurochemical injury. Several preliminary clinical studies also suggest worsened neurologic outcomes in patients who are febrile compared to those who are not. Unfortunately, however, a large prospective study of 428 patients with acute neurosurgical diseases has shown that fever is extraordinarily common during the first seven days after subarachnoid hemorrhage, stroke, and TBI. The ability to eliminate fever in most of these patients during the first five to seven days after their injury would seem desirable. Based on a phase-I trial, it appears that intravascular cooling is a promising new method for avoiding fever in the neurosurgical ICU.

Keywords: Hypothermia; Fever

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013397302

Publication date: 2001-10-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.